ZIOPHARM Oncology, Inc. is a biopharmaceutical company currently in developmental stage that seeks to acquire, develop and commercialize, on its own or with commercial partners, a diverse portfolio of cancer therapies. It is focused on two clinical stage product candidates: Ad-RTS-IL-12 &#x2B; veledimex and DC-RTS-IL-12 &#x2B; veledimex. Ziopharm Oncology was founded on September 9, 2003 and is headquartered in Boston, MA.
